Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 18Colorectal Neoplasms 17Stomach Neoplasms 10Colonic Neoplasms 7Gastrointestinal Neoplasms 2Adenocarcinoma 2Turcot syndrome 1Recurrence 1Rcctal Cancer 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Gastric Cancer 1Locally Advanced Colorectal Cancer 1Intestinal Neoplasms 1HER2-positive Locally Advanced Resectable Gastric Cancer 1HER2-positive Colorectal Cancer 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Carcinoma 1Adebrelimab (SHR-1316) 1

Interventions

Capecitabine 15Oxaliplatin 10spartalizumab 6Irinotecan 6tislelizumab 4Immune Checkpoint Inhibitors 4toripalimab 3Neoadjuvant Therapy 3sintilimab 2camrelizumab 2Radiation 2Fluorouracil 2Celecoxib 2nimotuzumab 1XELOX 1Thymalfasin 1Radiotherapy 1Leucovorin 1Injections 1HMPL-013 1Chemoradiotherapy 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Rectal Cancer × XELOX × Clear all
NCT05086627 2024-08-22

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Hebei Medical University Fourth Hospital

Phase 2 Completed
118 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡